# Zepbound Vision Loss: Does Tirzepatide Cause NAION?

Source: https://www.dietglp.com/blog/zepbound-vision-loss/
Published: 2026-11-10
Keywords: zepbound vision loss, does zepbound cause vision loss, can zepbound cause vision problems, zepbound blindness, zepbound and blurred vision, zepbound and eye problems, vision changes with zepbound, zepbound sudden vision loss, zepbound vision loss symptoms, naion vision loss zepbound, mounjaro vision loss, tirzepatide naion, zepbound vision loss lawsuit

**TL;DR:** Zepbound vision loss is rare, but on November 9, 2026 the FDA said every GLP-1 label, including Zepbound and Mounjaro (tirzepatide), must add a warning about NAION, an optic nerve problem that can cause sudden vision loss in one eye. Studies on tirzepatide disagree: one large records study found a small rise in NAION with semaglutide or tirzepatide, while another found fewer NAION cases on tirzepatide than on older GLP-1s. Get same-day care for sudden vision loss in one eye, and do not stop Zepbound on your own. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) keeps your daily protein and 20-minute workouts on track.

Can Zepbound cause vision loss? **The FDA now says the risk is real enough to warn about: on November 9, 2026, it required every GLP-1 medicine, including Zepbound and Mounjaro (tirzepatide), to add a warning about NAION, a rare problem that can cause sudden vision loss in one eye.** It is still rare. The FDA's trial data show a few extra cases per 100,000 people per year across the class. And the studies on tirzepatide itself point in different directions.

Most of the earlier news was about Ozempic and Wegovy. This guide is only about Zepbound and Mounjaro: what the label says, what the tirzepatide studies found, and what to do if your eyesight changes. For the full FDA action across all drugs, see [the FDA GLP-1 eye warning](/blog/fda-glp-1-eye-warning/).

## What is NAION?

NAION (non-arteritic anterior ischemic optic neuropathy) is like a small stroke of the optic nerve. Blood flow to the front of the nerve drops, and part of the nerve is hurt. It usually hits one eye, does not hurt, and often takes out the top or bottom half of what you see. It can be permanent.

It happens in people who never took a GLP-1, too. The FDA puts it at about 2.3 to 10.2 cases per 100,000 adults over 50 each year.

## Does Zepbound cause vision loss? What the tirzepatide studies show

No study has proven that tirzepatide causes NAION. Here is what the main data say, side by side.

| Source | Who was studied | What it found for tirzepatide |
|---|---|---|
| FDA review, Nov 9, 2026 | 126 trials (134,253 people) across GLP-1s | 6.4 vs 3.8 NAION cases per 100,000 person-years, GLP-1s vs comparators. Cases reported for every GLP-1, tirzepatide included |
| Wang et al., JAMA Network Open, Aug 2025 | 159,398 matched US adults with type 2 diabetes | Semaglutide or tirzepatide (grouped together): 0.04% got NAION in 2 years vs 0.02% on other diabetes drugs (HR 1.76) |
| Hong et al., Ophthalmology Retina, Jun 2026 | 102,590 matched pairs with type 2 diabetes | Tirzepatide had **fewer** NAION cases than older GLP-1s like semaglutide (HR 0.45), plus less diabetic retinopathy |
| Kakkar et al., Diabetes Obes Metab, Aug 2026 | FDA adverse event reports to late 2025 | 49 optic nerve reports for tirzepatide. A signal, but much weaker than semaglutide's (355 reports) |

So what does this mean? Two things can be true at once. Tirzepatide is now officially part of the NAION warning, because the FDA treats it as a class risk. But the best tirzepatide-only data so far do not show it is worse than other GLP-1s, and one large study suggests it may be lower. All of these are observational or report-based studies, so none of them can settle cause.

## What the Zepbound label says about your eyes today

As of November 10, 2026, the Zepbound label on openFDA (revised August 2026) does not list NAION yet. Lilly has to add it under the FDA order. The label already has two eye-related points:

- **Diabetic retinopathy (section 5.8).** In people with type 2 diabetes, fast improvement in blood sugar can briefly make diabetic retinopathy worse. People with a history of it should be monitored. The Mounjaro label has the same warning.
- **Blurred vision as a low blood sugar sign.** The Medication Guide lists blurred vision among signs of low blood sugar. That risk is higher if you also use insulin or a sulfonylurea.

Blurred vision is not listed as a common Zepbound side effect. If your vision gets blurry, do not guess the cause. Get it checked.

## Zepbound vision loss symptoms: when to get help

The FDA lists these NAION warning signs:

- Sudden, painless vision loss in one eye, often noticed when you wake up
- Blurry or missing parts of your view
- Colors that look washed out
- Central vision that is less sharp

Get care **the same day**. Call your doctor, an eye doctor, or go to urgent care. Tell them you take Zepbound or Mounjaro and your dose.

## Who has a higher risk?

The FDA names smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. A 2026 review in the Journal of the Endocrine Society added one more: a small, crowded optic nerve (a "disc at risk") that an eye doctor can see in an exam. If you have had NAION in one eye, the other eye is at higher risk.

Many of these risks are the same reasons people take Zepbound. That makes it hard to separate the drug from the disease. Zepbound is even approved for [obstructive sleep apnea](/blog/zepbound-sleep-apnea/), one of the NAION risk factors.

## Should you stop Zepbound?

Not on your own. The FDA did not tell people without symptoms to stop. If NAION happens, the FDA tells doctors to consider stopping unless the benefits clearly outweigh the risk, and that is a decision for you and your prescriber. If you have had NAION or another optic nerve problem before, bring it up before your next refill. Your doctor may suggest an eye exam first.

Stopping has costs, too, like weight regain and higher blood sugar. If you and your doctor decide to stop, read [how to stop a GLP-1 without rebound](/blog/how-to-stop-glp1-without-rebound/).

## What you can control while you are on Zepbound

You cannot control a rare eye event. You can control the habits that make the weight you lose mostly fat. Fast weight loss can take muscle with it, and eating enough protein and lifting a few times a week are the two best ways to keep it. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you one protein target, one 20-minute workout and one Shape Score a day, so you can see that the weight coming off is fat, not muscle. For the protein side, see [your protein target on GLP-1](/blog/protein-target-on-glp1/), and for the lifting side, [resistance training on GLP-1](/blog/resistance-training-on-glp1/).

If you have type 2 diabetes, keep your yearly dilated eye exam on the calendar. Our [GLP-1 and type 2 diabetes guide](/blog/glp1-and-diabetes/) covers why.

## Zepbound vs Mounjaro: same drug, same warning

Zepbound and Mounjaro are both tirzepatide from Eli Lilly. Zepbound is for weight and sleep apnea; Mounjaro is for type 2 diabetes. The NAION warning applies to both. See [Zepbound vs Mounjaro](/blog/zepbound-vs-mounjaro/) for how the two differ.

## Bottom line

Zepbound vision loss is rare, and it is not proven that tirzepatide causes it. The FDA now requires a NAION warning on all GLP-1 labels anyway, and the tirzepatide studies are mixed, with one large study showing a lower risk than older GLP-1s. Learn the warning signs, get same-day care for sudden vision loss in one eye, and keep medicine decisions with your prescriber. Then keep building protein and strength habits with [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138).

## Sources

- [FDA Drug Safety Communication: safety labeling changes for GLP-1 RAs due to potential increased risk of NAION, November 9, 2026](https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential)
- [Zepbound (tirzepatide) prescribing information, openFDA label effective August 2026](https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ZEPBOUND%22)
- [Wang et al., Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes, JAMA Network Open, 2025](https://pubmed.ncbi.nlm.nih.gov/40788646/)
- [Hong et al., Ocular Outcomes with Tirzepatide versus GLP-1 Receptor Agonists in Type 2 Diabetes, Ophthalmology Retina, 2026](https://pubmed.ncbi.nlm.nih.gov/41655764/)
- [Kakkar et al., Optic Ischaemic Neuropathy in Incretin-Based Therapy, Diabetes Obes Metab, 2026](https://pubmed.ncbi.nlm.nih.gov/42259643/)
- [Ruan et al., GLP-1 receptor agonists and risk of NAION, Journal of the Endocrine Society, 2026](https://pubmed.ncbi.nlm.nih.gov/42857401/)
- [Review of Optometry: GLP-1 drugs under scrutiny as lawsuits allege NAION risk](https://www.reviewofoptometry.com/news/article/glp1-drugs-under-scrutiny-as-lawsuits-allege-naion-risk)


## Frequently asked questions

**Q: Does Zepbound cause vision loss?**

A: It has not been proven. The FDA said on November 9, 2026 that NAION, a rare optic nerve stroke, has been reported with every GLP-1 on the market, including tirzepatide, and it is requiring a new warning on all of their labels. The added risk, if real, is a few cases per 100,000 people per year.

**Q: Can Zepbound cause vision problems like blurred vision?**

A: Blurred vision is not listed as a common side effect in the Zepbound label. It is listed as a possible sign of low blood sugar, which is more likely if you also take insulin or a sulfonylurea. The label also tells people with type 2 diabetes to report any vision changes, because fast drops in blood sugar can briefly worsen diabetic retinopathy.

**Q: What are the symptoms of NAION on Zepbound?**

A: Per the FDA: sudden, painless vision loss in one eye, often noticed on waking, blurry or missing parts of what you see, colors that look washed out, or less sharp central vision. Contact a health care professional right away.

**Q: Is Zepbound vision loss permanent?**

A: NAION can be permanent. The FDA says it may cause lasting loss of sight in some people, and the risk in the other eye goes up after the first eye is affected. Blurry vision from blood sugar swings is different and usually settles, but only an eye exam can tell them apart.

**Q: Does the new FDA eye warning apply to Mounjaro too?**

A: Yes. Mounjaro and Zepbound are both tirzepatide, and the FDA requirement covers all GLP-1 receptor agonists. As of November 10, 2026, the labels posted on openFDA (Zepbound August 2026, Mounjaro July 2026) had not yet been updated with NAION.

**Q: Should I stop Zepbound because of the vision warning?**

A: Do not stop on your own. The FDA did not tell people without symptoms to stop. If NAION happens, the FDA says to talk with your health care professional about whether to continue. If you have had NAION before, tell your prescriber before you start or keep taking Zepbound.

**Q: Is there a Zepbound vision loss lawsuit?**

A: News outlets have reported lawsuits over NAION against GLP-1 makers, mostly Novo Nordisk and, to a lesser degree, Eli Lilly. A lawsuit is not proof that a drug caused harm. For legal questions, talk to a lawyer; for medical questions, talk to your doctor.

